The pharmaceutical industry is the country's strategic partner. He demonstrated this during the pandemic, giving important support in the area to crisis management and developing treatments and vaccines against Covid-19 in less than a year. It demonstrates this every day by investing in research and guaranteeing the continuity of the supply of medicines, vaccines and therapies essential for preventing and treating diseases, which are often rare. It did so even in a difficult year like 2020: over 90% of drug companies confirmed investments in R&D and, of these, almost 40% increased them.
A partnership that has allowed the sector and the country to grow together over the years, spreading new knowledge, skills and best practices, nurturing a shared culture on the new frontiers of science and technology
A partnership with public and private research institutions, start-ups, science parks, non-profit organizations, without which it would not be possible to excel in all phases of the research process: from studies, to research and experimentation, up to access to treatment for patients. Collaborations that make the pharmaceutical industry one of the most advanced examples of Open Innovation.
The health crisis has made clear the need to further strengthen the collaboration between companies, institutions and the research system, to accelerate the innovation processes already underway and improve the health and life expectancy of citizens, attract new resources and talents for the economic and social development of the country.
An attractiveness that needs certain tools and rules to encourage basic research, clinical studies, the registration and protection of patents, the technological and digital transfer of information, making the Italian ecosystem of innovation stronger. For the benefit of today's and tomorrow's patients
